Beta

Vivani medical, inc.VANI.US Overview

US StockHealthcare
(No presentation for VANI)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

VANI AI Insights

VANI Overall Performance

VANI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VANI Recent Performance

-1.44%

Vivani medical, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

VANI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check VANI's Trend

VANI Key Information

VANI Valuation Metrics

VANI Profile

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Price of VANI

VANI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VANI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.45
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.00
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.45
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.00
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-100.00%

  • When is VANI's latest earnings report released?

    The most recent financial report for Vivani medical, inc. (VANI) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VANI's short-term business performance and financial health. For the latest updates on VANI's earnings releases, visit this page regularly.

  • How much cash does VANI have?

    At the end of the period, Vivani medical, inc. (VANI) held Total Cash and Cash Equivalents of 17.57M, accounting for 0.45 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is VANI's EPS continuing to grow?

    According to the past four quarterly reports, Vivani medical, inc. (VANI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VANI?

    Vivani medical, inc. (VANI)'s Free Cash Flow (FCF) for the period is -6.99M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 14.49% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of VANI?

    The latest valuation data shows Vivani medical, inc. (VANI) has a Price-To-Earnings (PE) ratio of -3.44 and a Price/Earnings-To-Growth (PEG) ratio of 0.16. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.